Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

Viloxazine has a long history of clinical use in Europe as an antidepressant, and has
recently been repurposed into an extended-release form for the treatment of attention …

The human intestinal absorption of 241 drugs was evaluated. Three main methods were
used to determine the human intestinal absorption: bioavailability, percentage of urinary …

As antiepileptic drugs (AEDs) and psychotropic agents are increasingly used in
combination, the possibility of pharmacokinetic interactions between these compounds is …

Although the standard tricyclic antidepressants (TCAs) are generally effective in the
treatment of depression, they can cause several troublesome adverse effects. Chief among …

Viloxazine is a recently approved, non-stimulant medication functions by inhibiting the
uptake of norepinephrine which has been seen to be decreased in patients with ADHD …

This article provides an overview of the pharmacokinetic drug–drug interactions (DDIs) for
agents prescribed for attention-deficit/hyperactivity disorder (ADHD). Polypharmacy in the …

Viloxazine extended‐release capsules (viloxazine ER; Qelbree) is a novel nonstimulant,
recently approved by the US Food and Drug Administration for the treatment of ADHD in …

Introduction Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental
disorder characterized by inattention and/or hyperactivity and impulsivity. Viloxazine …

The effect of viloxazine (150-300 mg daily for 21 days) on plasma phenytoin levels at steady
state was examined in 10 epileptic patients stabilised on a fixed phenytoin dosage. After …